Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ADCT-701 |
| Synonyms | |
| Therapy Description |
ADCT-701 is an antibody-drug conjugate (ADC) comprising an antibody targeting DLK-1 linked to the cytotoxic agent SG3199, which potentially decreases tumor growth (Cancer Res (2018) 78 (13_Supplement): 744). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ADCT-701 | ADCT701|ADCT 701 | ADCT-701 is an antibody-drug conjugate (ADC) comprising an antibody targeting DLK-1 linked to the cytotoxic agent SG3199, which potentially decreases tumor growth (Cancer Res (2018) 78 (13_Supplement): 744). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06041516 | Phase I | ADCT-701 | Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas | Recruiting | USA | 0 |